ReviewMediators of inflammation2012
Eicosanoids and respiratory viral infection: coordinators of inflammation and potential therapeutic targets.
Review in Mediators of inflammation, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
24 citing papers in PubMed, 43 citations in OpenAlex.
- Phospholipase A2 Isoforms in Lung Immunity and Respiratory Infections: Potential Targets for Next-Generation Therapy.International journal of molecular sciences · 2026Review
- Leukotriene B4 regulates T cell recognition and control of MCMV in mucosal tissues.Mucosal immunology · 2025Article
- Mass Spectrometry-Based Metabolomics Reveals a Salivary Signature for Low-Severity COVID-19.International journal of molecular sciences · 2024Article
- Membrane lipid composition of bronchial epithelial cells influences antiviral responses during rhinovirus infection.Tissue barriers · 2024Article
- Visual analysis on ferroptosis and its cross-talk to coronavirus disease 2019 (COVID-19).Heliyon · 2024Article
- Influenza A virus selectively elevates prostaglandin EiScience · 2024Article
- Article
- Article
- Lipidomics in Understanding Pathophysiology and Pharmacologic Effects in Inflammatory Diseases: Considerations for Drug Development.Metabolites · 2022Review
- Pharmaconutrition strategy to resolve SARS-CoV-2-induced inflammatory cytokine storm in non-alcoholic fatty liver disease: Omega-3 long-chain polyunsaturated fatty acids.World journal of clinical cases · 2021Review
- The role of 5-lipoxygenase in the pathophysiology of COVID-19 and its therapeutic implications.Inflammation research : official journal of the European Histamine Research Society ... [et al.] · 2021Review
- Pilot Study of Peak Plasma Concentration After High-Dose Oral Montelukast in Children With Acute Asthma Exacerbations.Journal of clinical pharmacology · 2021Observational
- The Use of the Anticoagulant Heparin and Corticosteroid Dexamethasone as Prominent Treatments for COVID-19.Frontiers in medicine · 2021Review
- Potential benefits and risks of omega-3 fatty acids supplementation to patients with COVID-19.Free radical biology & medicine · 2020Review
- Polygalasaponin F treats mice with pneumonia induced by influenza virus.Inflammopharmacology · 2020Article
- Transcriptome profiling in Rift Valley fever virus infected cells reveals modified transcriptional and alternative splicing programs.PloS one · 2019Article
- Adverse events are rare after single-dose montelukast exposures in children.Clinical toxicology (Philadelphia, Pa.) · 2018Article
- Ultra-weak photon emission as a dynamic tool for monitoring oxidative stress metabolism.Scientific reports · 2017Article
- Intake of vitamin C, vitamin E, selenium, zinc and polyunsaturated fatty acids and upper respiratory tract infection-a prospective cohort study.European journal of clinical nutrition · 2017Article
- Influenza A viruses suppress cyclooxygenase-2 expression by affecting its mRNA stability.Scientific reports · 2016Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
Viruses are frequent causes of respiratory infection, and viral respiratory infections are significant causes of hospitalization, morbidity, and sometimes mortality in a variety of patient populations. Lung inflammation induced by infection with common respiratory pathogens such as influenza and respiratory syncytial virus is accompanied by increased lung production of prostaglandins and leukotrienes, lipid mediators with a wide range of effects on host immune function. Deficiency or pharmacologic inhibition of prostaglandin and leukotriene production often results in a dampened inflammatory response to acute infection with a respiratory virus. These mediators may, therefore, serve as appealing therapeutic targets for disease caused by respiratory viral infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.